For US Residents

For US Residents

Visit NUCALA (mepolizumab) homepage

    MYNUCALA MOBILE SMS PROGRAM TERMS & CONDITIONS

    This initiative is being sponsored by GlaxoSmithKline (GSK) (the “initiative”).

    Initiative Period: July 1, 2021 - ongoing

    How does the text messaging program work? Individuals will enroll via a web registration form. By opting into the NUCALA (mepolizumab) mobile text program, you consent to receive recurring text message medication reminders.

    You will receive a text message prompting you to set a date for your next refill reminder. You will receive recurring refill reminders every 28 days to remind you to contact your pharmacy. Reminder messages include prompts to reset your reminder date if necessary. Message and data rates may apply. Up to 7 text messages per month. Participation in the program is not a condition of purchase or use of any GSK product. For additional information regarding how GSK handles your information, please see our privacy notice.

    Participant Requirements: You must have a wireless device capable of 2-way messaging, be using a participating wireless carrier, and be a wireless service subscriber with text messaging service. Not all cellular phone providers carry the necessary service to participate. Check your phone capabilities for specific text messaging instructions.

    Participant Opt-Out or Help: You may opt-out from participating at any time. Text STOP to 96094 or reply STOP to any of our messages to opt-out. For help, text HELP to 96094 or reply HELP to any of our messages, go to https://contactus.gsk.com/callback.html, or call 1-888-825-5249.

    Privacy Policy: http://us.gsk.com/en-us/privacy/

    Notices

    Costs: You will be charged the standard text messaging fee charged by your wireless carrier for each message you send or receive, in accordance with the terms of your cellular subscription plan. Other carrier-specific rates may apply, depending on your individual wireless pricing plan, in accordance with your wireless customer agreement. You are responsible for all applicable taxes. Consult your wireless service provider regarding its pricing plans. Participating Wireless Carriers: Alltel, AT&T Mobility, Cellular One, MetroPCS, Nextel, Sprint, T-Mobile, Verizon Wireless, and Virgin Mobile. The service is offered on an “as-is” basis and may not be available in all areas at all times and may not continue to work in the event of product, software, coverage or other changes made by your wireless carrier. Carriers are not liable for delayed or undelivered messages.

    Rights

    Releases; No Warranties; Reservations

    By participating, you agree to release and hold harmless Twilio and Participating Wireless Carriers (“Released Parties”) and their respective representatives, agents, successors, assigns, employees, officers and directors, from any and all liability, for loss, harm, damage, injury, cost or expense whatsoever including without limitation, property damage, personal injury and/or death which may occur in connection with this initiative, and for any claims based on violation of law or infringement or violation of any rights of any person or entity, including, without limitation, violation of publicity rights, defamation, invasion of privacy.

    Released Parties are not responsible for any printing, typographical, mechanical or other errors in associated promotional materials in connection with this initiative. Participating Wireless Carriers and/or each of their respective subsidiaries, affiliates, shareholders, officers, directors, agents, representatives and employees are not responsible for this initiative, and none of them will have any liability or responsibility for any claim arising in connection with participation in this initiative.

    The Released Parties make no warranties, and hereby disclaim any and all warranties, express or implied, concerning any prize or content furnished by third parties in connection with this initiative. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ALL SERVICES ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND THE RELEASED PARTIES HEREBY DISCLAIM ALL SUCH WARRANTIES, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND/OR NON-INFRINGEMENT.

    Released Parties are not responsible for technical, hardware, software, electronic, network, telephone or other communications malfunctions, errors or failures of any kind, errors in transmission, traffic congestion, lost or unavailable network connections, telephone connections, wireless phone connections, web site, internet, or ISP availability, unauthorized human intervention, incomplete or inaccurate capture of entry information (regardless of cause) or failed, incomplete, garbled, jumbled or delayed transmissions which may limit or restrict your ability to send a message, including any injury or damage to your or any other person’s wireless device relating to or resulting from participating in this initiative.

    GSK reserves the right, in its sole discretion, to cancel, terminate, modify, extend or suspend this initiative for any reason without notice, including, without limitation, virus bugs, non-authorized human intervention, fraud or other causes beyond its control, including, without limitation, anything that affects the administration, security, fairness or proper conduct of this initiative.

    Talk to your doctor to see if adding NUCALA is right for you.

    Approved Uses & Safety Info

    Approved Uses

    Important Safety Information

    Approved Uses

    NUCALA is a prescription medicine for the:

    • add-on maintenance treatment of patients 6 and older with severe eosinophilic asthma. NUCALA is not used to treat sudden breathing problems.
    • add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults whose disease is not controlled with nasal corticosteroids.
    • add-on maintenance treatment of eosinophilic chronic obstructive pulmonary disease (COPD) in adults whose disease is not controlled. NUCALA is not used to treat sudden breathing problems.
    • treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA).
    • treatment of people 12 years of age and older with hypereosinophilic syndrome (HES) for 6 months or more.

    Important Safety Information

    Do not use NUCALA if you are allergic to mepolizumab or any of the ingredients in NUCALA.

    Do not use to treat sudden breathing problems.

    NUCALA can cause serious side effects, including:

    • allergic (hypersensitivity) reactions, including anaphylaxis. Serious allergic reactions can happen after you get your NUCALA injection. Allergic reactions can sometimes happen hours or days after you get a dose of NUCALA. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
      • swelling of your face, mouth, and tongue
      • breathing problems
      • fainting, dizziness, feeling lightheaded (low blood pressure)
      • rash
      • hives
    • herpes zoster infections that can cause shingles have happened in people who received NUCALA.

    Before receiving NUCALA, tell your healthcare provider about all of your medical conditions, including if you:

    • are taking oral or inhaled corticosteroid medicines. Do not stop taking your other medicines, including your corticosteroid medicines, unless instructed by your healthcare provider because this may cause other symptoms to come back.
    • have a parasitic (helminth) infection.
    • are pregnant or plan to become pregnant. It is not known if NUCALA may harm your unborn baby.
    • are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will use NUCALA and breastfeed. You should not do both without talking with your healthcare provider first.
    • are taking prescription and over-the-counter medicines, vitamins, and herbal supplements.

    The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a burning feeling at the injection site), back pain, and tiredness (fatigue). Mouth/throat pain and joint pain have been reported with CRSwNP. Diarrhea and cough have been reported with COPD.

    Please see full Prescribing Information for NUCALA.

    You are encouraged to report negative side effects of prescription drugs to the FDA.
    Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report negative side effects to GSK at gsk.public.reportum.com or 1-888-825-5249.
    Visit GSK Help Center website

    Explore the GSK Help Center website to find customer service support and contact information.

    Visit GSK For You website

    If you have questions about how to access your GSK medication or need cost information, visit gskforyou.com or call 1-866-GSK-FOR-U (1-866-475-3678).